中国中西医结合急救杂志
中國中西醫結閤急救雜誌
중국중서의결합급구잡지
INTEGRATED TRADITIONAL CHINESE AND WESTERN MEDICINE IN PRACTICE OF CRITICAL CARE MEDICINE
2015年
1期
72-74
,共3页
冠心病%和肽素%肿瘤坏死因子-α%白细胞介素-10
冠心病%和肽素%腫瘤壞死因子-α%白細胞介素-10
관심병%화태소%종류배사인자-α%백세포개소-10
Coronary heart disease%Copeptin%Tumor necrosis factor-α%Interleukin-10
目的：观察活血通脉胶囊对冠心病心血瘀阻证患者血浆小分子代谢产物的调节作用。方法采用前瞻性研究方法，选择2009年1月至2013年12月在天津市大港地区就诊的136例冠心病心血瘀阻证患者，按简单随机抽样方法分成两组。对照组（68例）采用硝酸酯类、β受体阻滞剂、钙离子拮抗剂及肠溶阿司匹林等常规疗法；活血通脉胶囊组（68例）在常规治疗基础上给予活血通脉胶囊，每次4粒（每粒0.25 g），每日3次，30 d为1个疗程，共3个疗程。评定两组治疗后临床疗效和心电图疗效；采用酶联免疫吸附试验（ELISA）检测血浆和肽素、肿瘤坏死因子-α（TNF-α）及白细胞介素-10（IL-10）水平，计算TNF-α/IL-10比值。结果活血通脉胶囊组临床疗效及心电图疗效均明显高于对照组〔临床总有效率：89.71%（61/68）比80.88%（55/68）；心电图总有效率：57.35%（39/68）比48.53%（33/68），均P＜0.05〕。两组治疗后和肽素及TNF-α/IL-10比值均较治疗前明显降低，且以活血通脉胶囊组降低更显著〔和肽素（ng/L）：0.22±0.04比0.31±0.05，TNF-α/IL-10比值：0.49±0.11比0.65±0.09，均P＜0.05〕。结论在常规疗法基础上加用活血通脉胶囊能通过降低和肽素水平及TNF/IL-10比值来改善冠心病心血瘀阻证患者的治疗效果。
目的：觀察活血通脈膠囊對冠心病心血瘀阻證患者血漿小分子代謝產物的調節作用。方法採用前瞻性研究方法，選擇2009年1月至2013年12月在天津市大港地區就診的136例冠心病心血瘀阻證患者，按簡單隨機抽樣方法分成兩組。對照組（68例）採用硝痠酯類、β受體阻滯劑、鈣離子拮抗劑及腸溶阿司匹林等常規療法；活血通脈膠囊組（68例）在常規治療基礎上給予活血通脈膠囊，每次4粒（每粒0.25 g），每日3次，30 d為1箇療程，共3箇療程。評定兩組治療後臨床療效和心電圖療效；採用酶聯免疫吸附試驗（ELISA）檢測血漿和肽素、腫瘤壞死因子-α（TNF-α）及白細胞介素-10（IL-10）水平，計算TNF-α/IL-10比值。結果活血通脈膠囊組臨床療效及心電圖療效均明顯高于對照組〔臨床總有效率：89.71%（61/68）比80.88%（55/68）；心電圖總有效率：57.35%（39/68）比48.53%（33/68），均P＜0.05〕。兩組治療後和肽素及TNF-α/IL-10比值均較治療前明顯降低，且以活血通脈膠囊組降低更顯著〔和肽素（ng/L）：0.22±0.04比0.31±0.05，TNF-α/IL-10比值：0.49±0.11比0.65±0.09，均P＜0.05〕。結論在常規療法基礎上加用活血通脈膠囊能通過降低和肽素水平及TNF/IL-10比值來改善冠心病心血瘀阻證患者的治療效果。
목적：관찰활혈통맥효낭대관심병심혈어조증환자혈장소분자대사산물적조절작용。방법채용전첨성연구방법，선택2009년1월지2013년12월재천진시대항지구취진적136례관심병심혈어조증환자，안간단수궤추양방법분성량조。대조조（68례）채용초산지류、β수체조체제、개리자길항제급장용아사필림등상규요법；활혈통맥효낭조（68례）재상규치료기출상급여활혈통맥효낭，매차4립（매립0.25 g），매일3차，30 d위1개료정，공3개료정。평정량조치료후림상료효화심전도료효；채용매련면역흡부시험（ELISA）검측혈장화태소、종류배사인자-α（TNF-α）급백세포개소-10（IL-10）수평，계산TNF-α/IL-10비치。결과활혈통맥효낭조림상료효급심전도료효균명현고우대조조〔림상총유효솔：89.71%（61/68）비80.88%（55/68）；심전도총유효솔：57.35%（39/68）비48.53%（33/68），균P＜0.05〕。량조치료후화태소급TNF-α/IL-10비치균교치료전명현강저，차이활혈통맥효낭조강저경현저〔화태소（ng/L）：0.22±0.04비0.31±0.05，TNF-α/IL-10비치：0.49±0.11비0.65±0.09，균P＜0.05〕。결론재상규요법기출상가용활혈통맥효낭능통과강저화태소수평급TNF/IL-10비치래개선관심병심혈어조증환자적치료효과。
Objective To observe traditional Chinese medicine (TCM) Huoxue Tongmai capsules (HXTMC) for the regulation of small molecule metabolites in plasma of patients with coronary heart disease and TCM blood stasis syndrome. Methods A prospective study was conducted in which 136 patients with coronary heart disease and blood stasis syndrome treated in Dagang district in Tianjin from January 2009 to December 2013 were selected and randomly divided into two groups:control group (68 cases) and HXTMC group (68 cases). The control group received the conventional oral therapy with nitrates, β receptor blockers, calcium antagonists, enteric coated aspirin, etc, and the HXTMC group received the conventional therapy and additionally oral administration of HXTMC, 4 capsules each time (each capsule 0.25 g), trice a day, 30 days constituting a therapeutic course, 3 courses in total. According to the standard of curative effect evaluation of angina pectoris in coronary heart disease, the clinic total curative effects of angina pectoris and electrocardiogram (ECG) were evaluated. The concentrations of copeptin, tumor necrosis factor-α(TNF-α) and interleukin-10 (IL-10) in the plasma were tested by enzyme-linked immunosorbent assay (ELISA), and the TNF-α/IL-10 ratio was calculated. Results The total clinical effective rates of patients and the ECG in HXTMC group were significantly higher than those of the control group [clinic total effective rates:89.71%(61/68) vs. 80.88%(55/68), ECG total effective rates:57.35%(39/68) vs. 48.53%(33/68), both P<0.05]. Concentration of copeptin and TNF-α/IL-10 ratio in the plasma after treatment of the both groups were significantly lower than those before treatment, and the changes were more obvious in HXTMC group [copeptin (ng/L): 0.22±0.04 vs. 0.31±0.05, TNF-α/IL-10 ratio:0.49±0.11 vs. 0.65±0.09, both P<0.05]. Conclusion Addition of HXTMC to conventional therapy for treatment of patients with coronary heart disease accompanied by blood stasis syndrome can lower the plasma level of copeptin and TNF-α/IL-10 ratio, thus it may improve the clinical curative effects of the patients.
